Skip to content
‹ Back to IndustriesSciences

Can Scientists Use ChatGPT for Scientific Research?

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers. The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · · Ai ToolsArtificial IntelligenceChatgptResearch Methods
Share

Key takeaways

01

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers.

02

The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient….

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers. The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient. Surprisingly for the academic community, the experiment proved successful, with their research finding that OpenAI’s models “can capture the concepts in the scholarly text and produce high-quality revisions that improve clarity.” More readable and accessible academic manuscripts sounds like a win for everyone involved, but how else can AI-supported chatbots support the academic community? Greene and Pividori’s research leaves many wondering whether scientists dealing in rigorous and highly-technical subjects can leverage ChatGPT for scientific research from start to finish.

ChatGPT was launched in November 2022 and got over 1 million users within the first week of its launch; OpenAI’s tool is clearly highly popular and gaining mainstream appeal, validating new use cases every week. The tool can perform complex tasks that save loads of time and energy, and can produce text like poetry, prose, computer code, and even topical research ideas. However, it’s not a perfect tool by any stretch. High level thought leaders in the tech community, including Steve Wozniak, warn that ChatGPT’s text generation can be riddled with errors. Obviously, anything of academic quality can’t have erroneous revisions applied.

Scientists use various types of research methods to gather information to develop their hypotheses and supplement academic texts, including digging for sources, conducting hypothetical scientific models to prove their research, running surveys for new data, and more. With ChatGPT Plus hot on our heels, should scientists start to use ChatGPT for scientific research? How confident can they be in its efficacy? Justin Bean, author of What Could Go Right and an experienced sustainability and smart city strategist working with Fortune 500s and cutting-edge start-ups, weighs in with his take. Bean is highly familiar with the research process; he spent many years as a clean tech and green energy consultant, where he conducted layered and rigorous research of financial data, venture capital investments, trend reports and more.

Justin’s Thoughts:

“So, if Siri gave everyone a digital assistant, ChatGPT gives everyone a digital intern. This means it can do way more work for us and including in science. So, a lot of the work in science and data analysis is all about gathering and blending and cleaning and compiling data, and about making interpretations that lead to some kind of insight, which they can then take and do science with.

Now because of ChatGPT, a lot of that early stage can be done by an AI and that’ll free up scientists to have a lot more time doing the science. But not just that, it’s going to free a lot of people up to be able to do science who aren’t conventional scientists and people who don’t have PhDs. This is because it’s going to do a lot of that initial work and be able to explain it in everyday layman’s terms for you and me to be able to do the science.

And I think that’s going to democratize a lot of inventions and a lot of science as innovators from around the world and different perspectives, it will bring their perspectives to science and leverage the information they can get through chatGPT. Now, as this develops, all these AIs are going to become more and more specialized.

So you may have a specialized artificial intelligence for cancer science and detection, and another one for weather science or climate science. Many different ones will proliferate. In addition, we’re going to have autonomous economic agents that will take that information and go out and acquire materials or goods or contracts for us just to make a lot of that process a lot easier and make us all more effective.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz's AAV2 gene therapy for retinitis pigmentosa, through IND-enabling work and a planned Phase 1/2 trial. CLZ002 targets retinal repair, not mutations. Because the disease is linked to more than 90 genes, one manufacturing process could end up serving a broad patient group.

  • 01Retinitis pigmentosa has more than 90 causal genes; CLZ002 aims at a shared retinal repair pathway, so a single AAV2 manufacturing process would serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab hiring budgets for 2027 carry a net outlook of just +2, down from +10, while consumables sit at +30 and raw materials at +31. Labs are paying for supplies and planning capital purchases further ahead. New positions face the toughest scrutiny.

  • 01Labs heading into 2027 expect their reagent budgets to grow and their headcount budgets to stall: consumables carry a net outlook of +30, hiring just +2.
  • 02Lab Manager’s read: if consumables spending stays flat, the lab is probably buying less—because respondents reported rising costs across many supply items, from reagents to shipping.
  • 03Hiring gets treated as a recurring cost, not a one-time purchase; one published example estimates ~$46,000/year for a graduate student and $80,000–$100,000 for a postdoc (with fringe) at one institution. Lab Manager recommends justifying new roles with throughput, turnaround and risk—while separating price from volume in supply-line requests.

Nov 13, 2026

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra BioPharma Solutions opened Building H, a $250 million-plus addition to its Bloomington, Indiana campus, featuring two syringe lines and a vial line with lyophilizers. The CDMO plans to expand from 11 to 18 filling lines by 2027. Extra sites reduce supply risk only when products are qualified at both locations.

  • 01Simtra's network is set to grow from 11 to 18 filling lines across Indiana and Germany by 2027, a published capacity timeline sponsors can plan tech transfers against.
  • 02A second fill site cuts supply risk only after a product has been validated there; for biologics that means process validation, comparability work and regulatory filings first.
  • 03Programs whose real exposure sits in concentrated starting-material supply gain little from added fill-finish redundancy, however well the new lines are built.

Nov 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512